MedWatch

ALK to exit Turkish market: "It's bad business if all we get is peanuts"

A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.

ALK's Turkish workforce will have look for employment elsewhere | Photo: ALK / PR

Getting a viable business running in Türkiye has proved difficult for ALK, which is why the Danish allergy firm has decided to pack up and leave the country.

”The entire regulatory environment, the authorization environment for our products, in addition to the market environment, made it unfeasible for us to establish a coherent business there,” ALK’s chief executive officer, Carsten Hellmann, tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs